A molecule your body already uses to make NAD+.
NMN for women
NMN for Women: Benefits, Dosage, Menopause, and What Human Studies Show
NMN has become one of the most talked-about supplements in healthy aging.
The basic reason is simple: your body uses NMN to make NAD+, a coenzyme every cell needs for energy metabolism and other essential cellular processes.
And this is not only a male-biohacker story.
Women have been studied directly. That includes postmenopausal women and women in their 40s and 50s.
Across human research, the clearest and most consistent finding is that taking NMN raises NAD+ or related NAD metabolites. In women specifically, researchers have also reported a meaningful metabolic effect in a randomized trial, along with early findings involving sleep, fatigue, skin, and hair in smaller studies.
This guide explains what that means for a woman deciding whether NMN belongs in her routine.
Published full-text scientific publications reviewed
Published intervention studies specifically in women
Human studies prioritized
Evidence reviewed September 2026
The quick answer
NMN for Women in 30 Seconds
Save this summary
Oral NMN raises NAD+ or related NAD metabolites in human studies.
Yes. Three published intervention studies in this review were conducted specifically in women.
Improved skeletal-muscle insulin sensitivity in a randomized trial of postmenopausal women with prediabetes.
250 mg, 300 mg, and 500 mg per day.
As a daily NAD+ and cellular-health supplement within a broader healthy-aging routine.
The useful answer
What Does NMN Do for Women?
NMN gives your body more of a molecule it already uses to make NAD+.
That is the simplest and most useful answer.
NAD+ is required for the redox reactions cells use to turn nutrients into usable energy. It is also used by enzymes involved in normal cellular signaling and maintenance.
NMN sits one step upstream.
Your body uses NMN as a precursor to make NAD+.
In human studies, oral NMN consistently raises circulating NAD+ or related metabolites.
That is why the strongest reason to take NMN today is not a vague promise to “reverse aging.”
It is much more concrete:
NMN supports the NAD+ pathway by supplying a precursor your body already uses.
NMN → NAD+ → Cellular processes
Step 01
You take NMN.
Step 02
Your body uses NMN to make NAD+.
Step 03
NAD+ participates in cellular energy metabolism and other NAD+-dependent processes.
For a deeper introduction to the molecule, read what NMN is. You can also explore what current human data show about NAD+ levels by age.
Why midlife matters
Why Are Women Interested in NMN After 40?
Menopause can add another layer to that conversation.
NMN is relevant here because it sits inside cellular metabolism rather than hormone replacement.
Researchers are studying whether increasing NMN availability can support NAD+ biology and influence measurable functions that matter as we age.
That includes metabolism, physical function, sleep, and other outcomes.
The evidence is not equally developed in every area.
But women are no longer absent from the research.
That matters.
For the wider foundations around movement, sleep, nutrition, and long-term health, explore Aging Well After 40.
Direct evidence in women
What Have Human Studies in Women Actually Found?
Three published intervention studies in the CELLSHE evidence review were conducted specifically in women.
They do not all carry the same weight.
Together, they give us a much clearer starting point than simply saying “NMN has been studied in humans.”
Three Studies. Three Amounts. Three Useful Takeaways.
Published intervention studies conducted specifically in women.
250 mg
Controlled metabolic result
300 mg
Early postmenopausal sleep, fatigue, and skin signals
500 mg
Early hair and fatigue findings
250 mg/day for 10 Weeks: The Strongest Controlled Evidence
Yoshino et al., Science, 2021
- Who
- 25 postmenopausal women with overweight or obesity and prediabetes.
- Design
- Randomized, double-blind, placebo-controlled.
- What they took
- 250 mg NMN per day for 10 weeks.
What researchers found
NMN improved insulin-stimulated glucose disposal in skeletal muscle and improved muscle insulin-signaling and remodeling endpoints.
Why it matters
This is the most important direct women-specific NMN study in the current evidence base.
It did not only show a change in an NAD+ biomarker.
It found a measurable physiological effect in women.
Because the study was randomized and placebo-controlled, it carries more weight than the smaller uncontrolled women-only studies below.
CELLSHE takeThis is the strongest direct evidence so far that NMN can influence a meaningful metabolic process in women.
300 mg/day for 8 Weeks in Postmenopausal Women
Morita et al., Glycative Stress Research, 2022
- Who
- 17 postmenopausal women aged 50-80 enrolled. Sixteen completed the study.
- Design
- Single-arm, uncontrolled.
- What they took
- 300 mg NMN per day after breakfast for 8 weeks.
What researchers found
The study measured a broad range of biomarkers and subjective outcomes.
Subjective skin, sleep, and fatigue scores showed positive signals during the study.
Estradiol and several other measured hormones did not significantly change.
One participant withdrew after a persistent mild headache.
Why it matters
This study gives us direct information from postmenopausal women.
Its subjective findings are early, but they identify areas worth testing in larger controlled trials.
500 mg/day for 12 Weeks in Women Aged 40-50
Fukumoto et al., Cosmetics, 2025
- Who
- 15 healthy Japanese women aged 40-50 with hair concerns.
- Design
- Single-arm, pre/post intervention.
- What they took
- 500 mg NMN per day for 12 weeks.
What researchers found
Several hair-related measures changed positively during the study, including selected measures of hair elongation density, shaft diameter, and cuticle condition.
Subjective hair-quality and fatigue measures also improved.
Why it matters
This is direct human evidence in women using 500 mg per day.
The findings are preliminary, but the study is useful both for female-specific research and for understanding the amounts used in published human work.
The realistic hierarchy
What Are the Most Realistic Benefits of NMN for Women?
NMN is easier to understand when we stop treating every possible outcome as equally established.
The NMN Evidence Ladder
- Most establishedRaises NAD+ or related metabolites in humans.
- Strong direct women-specific findingImproved skeletal-muscle insulin sensitivity in one randomized postmenopausal trial.
- Promising human researchPhysical function and selected metabolic outcomes.
- Early human signalsSleep, fatigue, skin, and hair.
- Early-stage researchFemale reproductive and ovarian aging.
1 · Strongest reason
NAD+ Support Is the Strongest Reason to Take NMN
Multiple human trials show that oral NMN raises NAD+ or related metabolites.
This is the most consistent result across the clinical research.
It is also the biological reason NMN is used as a supplement in the first place.
If your goal is to support NAD+ biosynthesis, this is the strongest part of the evidence.
Metabolic Health Has an Important Women-Specific Result
In the Yoshino randomized trial, 250 mg/day improved skeletal-muscle insulin sensitivity in postmenopausal women with prediabetes.
This matters because researchers observed a physiological effect, not only a biomarker change.
It is the clearest direct women-specific outcome in the current evidence base.
Physical Function Has Promising Human Research
Broader human trials have studied walking, exercise capacity, lower-limb function, and other performance outcomes.
Several trials have reported positive functional signals.
The results vary by population and test, so physical performance is a promising area rather than the primary reason to take NMN.
Sleep and Fatigue Are Interesting Early Signals
Sleep, drowsiness, and fatigue have appeared in several human studies, including research involving postmenopausal women.
These findings are not yet as established as the NAD+ response.
They are still relevant because they relate directly to daily function and quality of life.
Hair Is an Early Women-Specific Research Area
A small women-only study using 500 mg/day reported positive changes in selected hair measures and subjective hair quality.
This is early evidence.
It gives researchers a clear question to test next in a controlled trial.
Reproductive Aging Is Still Mostly a Preclinical Research Field
NMN has produced interesting ovarian and oocyte findings in animal and laboratory research.
That makes reproductive aging an active scientific area.
It does not make NMN a fertility treatment for women.
Midlife context
NMN and Menopause: Where Does It Actually Fit?
NMN is relevant to the menopause conversation for one important reason:
Some of the direct human research has been conducted in postmenopausal women.
The useful question is where NMN fits.
NMN is not a hormone.
It supplies a precursor your body uses to make NAD+.
That places it on the healthy-aging and cellular-health side of midlife rather than the hormone-replacement side.
Does NMN Increase Estrogen?
A small eight-week study in postmenopausal women measured estradiol directly.
Estradiol did not significantly change.
So the reason to take NMN is not to raise estrogen.
Can NMN Help During Menopause?
Think of NMN as part of the healthy-aging side of midlife.
The strongest direct postmenopausal evidence involves skeletal-muscle insulin sensitivity.
If your primary goal is treating hot flashes, night sweats, vaginal symptoms, or another menopause symptom, that is a different treatment decision.
Treat menopause symptoms appropriately.
Support healthy aging appropriately.
Can I Take NMN With HRT?
Human research has not established a special benefit from combining NMN with hormone therapy.
They also target very different biological systems.
If you use prescription hormone therapy, include NMN on the supplement list you review with the clinician managing your treatment.
Where NMN Fits in Midlife
Your Midlife Health
Menopause care
- Hormones
- Symptoms
- Individual medical treatment
Healthy-aging routine
- Movement
- Protein
- Sleep
- NAD+ support
- Other lifestyle foundations
Research-grounded amounts
How Much NMN Should a Woman Take?
Online NMN dosing can become complicated very quickly.
The human research gives us a simpler starting point.
Broader human studies have tested a wider range of daily amounts.
There is no validated formula that assigns women a different dose simply because they are women.
There is also no validated dose-by-age or dose-by-body-weight formula.
Amounts Studied in Women
250 mg/day
10 weeks
Randomized postmenopausal metabolic trial
300 mg/day
8 weeks
Postmenopausal women
500 mg/day
12 weeks
Healthy women aged 40 to 50
Is 500 mg a Sensible NMN Amount?
500 mg is a research-grounded human serving.
It has been used directly in a published women-only study.
It also sits comfortably inside the wider range studied in adult NMN research.
That does not make 500 mg the only possible amount.
It makes it a serious, clearly disclosed serving rather than a marketing number.
When Should You Take NMN?
Most human NMN studies use daily dosing.
For a real-world routine, consistency matters more than creating an elaborate timing protocol.
Morning is a simple habit anchor.
Follow the directions on the product you use.
There is no convincing human evidence that one precise hour is required for NMN to work.
What human trials report
Is NMN Safe for Women?
Direct answer
Short-term human safety data are generally reassuring.
A 2026 systematic review and meta-analysis of randomized NMN studies found no significant increase in overall adverse events, serious adverse events, withdrawals due to adverse events, or the major system-specific adverse-event categories assessed.
Human studies have tested NMN across multiple doses for periods ranging from days to several months. Across those trials, NMN has generally been well tolerated.
What Side Effects Have Been Reported?
When adverse events have occurred in trials, they have generally been mild.
In the small postmenopausal Morita study, one participant withdrew because of a persistent mild headache.
Across the larger randomized evidence base, adverse events were not significantly more common overall with NMN than with control.
What About Long-Term Use?
Most human NMN research is still measured in weeks or months.
That gives us useful short-term safety information.
Multi-year human safety data are not yet available.
Pregnancy and Breastfeeding
NMN has not been adequately studied during pregnancy or breastfeeding.
Do not start it in those situations without specific medical guidance.
Prescription Medications
If you take prescription medication or are under medical care, show your clinician the complete supplement label before adding NMN.
A transparent label makes that conversation much easier.
A practical fit check
Should NMN Be Part of Your Routine?
This is the decision the page should help you make.
NMN may be a good fit to consider if:
- You are interested in healthy aging and cellular health.
- Supporting NAD+ biology is one of your priorities.
- You prefer a simple daily supplement rather than an elaborate stack.
- You want an ingredient studied directly in humans and in women.
- You care about a clearly disclosed dose and independent testing.
- You are comfortable with a supplement whose strongest evidence is biological and metabolic rather than a stimulant-style feeling.
The decision in one sentence
If you want a simple, human-studied NAD+ precursor as part of a broader healthy-aging routine, NMN is a reasonable supplement to consider.
Keep the full decision framework on one page for your own reference.
The NMN Decision Guide for Women
What to know before you decide whether NMN belongs in your routine.
What NMN Does
NMN is a precursor your body uses to make NAD+, a coenzyme required for cellular energy metabolism and other NAD+-dependent processes.
What Human Research Shows Most Consistently
Oral NMN raises NAD+ or related metabolites in human studies.
What Women-Specific Research Has Found
The strongest women-specific controlled trial found improved skeletal-muscle insulin sensitivity in postmenopausal women with prediabetes.
Amounts Used in Women-Specific Studies
250 mg/day300 mg/day500 mg/day
NMN May Fit Your Goal If
- You want to support NAD+ biology.
- You want a simple healthy-aging supplement.
- You prefer a clearly disclosed single ingredient.
- You value human research and transparent testing.
Before You Buy
- Exact beta-NMN amount is shown.
- No proprietary blend hides the dose.
- Finished product is third-party tested.
- COA is available.
- Dose sits within published human research.
- Formula matches what you actually want.
Important Safety Check
Pregnant or breastfeeding: NMN is not adequately studied.
Prescription medication or medical care: review the complete label with your clinician.
The Simple Take
NMN is best understood as a daily NAD+ precursor within a broader healthy-aging routine.
Read the label, not the hype
How to Choose an NMN Supplement
Once you decide that you want NMN, choosing the product should not be complicated.
Ignore the biggest front-label number. Check these instead.
How Much Actual NMN Is in One Serving?
Look for the amount of NMN itself.
Not the weight of a blend. Not a proprietary complex. Not a front-label number that includes other ingredients.
Is It Beta-NMN?
Beta-NMN is the beta form of nicotinamide mononucleotide used in many human NMN studies.
The word “beta” does not mean a stronger dose. It tells you which molecular form is in the product.
Is the Dose Clearly Disclosed?
You should know exactly how much beta-NMN you are taking before you buy.
Has the Finished Product Been Independently Tested?
Supplements are only useful if the bottle contains what the label says it contains.
Look for third-party finished-product testing from an appropriately accredited laboratory.
Can You See a Certificate of Analysis?
A COA lets you inspect testing instead of relying only on marketing copy.
Does the Formula Match What You Actually Want?
If you want NMN, a single-ingredient NMN formula is the simplest option.
A larger stack only makes sense if you intentionally want the additional ingredients.
The CELLSHE formula
Why CELLSHE Uses 500 mg of Beta-NMN
Commercial disclosure: CELLSHE publishes this guide and also makes NMN 500.
CELLSHE NMN 500 provides 500 mg of beta-NMN in one capsule.
We chose 500 mg for a straightforward reason. It is a substantial amount with direct human research context behind it.
A women-only human study used 500 mg per day for 12 weeks, and 500 mg sits within the wider range used across published adult NMN research.
That gives us a clear research-grounded serving without turning the product into a dose-escalation contest.
Inside CELLSHE NMN 500
One ingredient. One capsule. A research-grounded serving.
- 500 mg beta-NMNOne active ingredient
- One capsule per day30 capsules and 30 daily servings
- Third-party testedTesting through an ISO/IEC 17025-accredited laboratory
- Certificate of Analysis availableThe testing is inspectable
- Non-hormonalA simple NAD+ precursor formula
For the woman who wants NMN without building an elaborate supplement stack, this is what we built.
Testing you can inspect
NMN 500 is third-party tested through an ISO/IEC 17025-accredited laboratory. The Certificate of Analysis lets you inspect the reported potency, heavy-metals, and microbiological results instead of relying only on marketing copy.
View the Certificate of Analysis
Purchase options
Choose one-time or monthly delivery
- 30 capsules and 30 daily servings
- No recurring delivery
- Monthly delivery
- Free U.S. subscription shipping
- CELLSHE Circle included
- Pause, skip, or cancel under current subscription terms
The complete source library
Want to Audit the Science Yourself?
You do not need to read 46 scientific publications to decide whether NMN interests you. But you should be able to if you want to.
CELLSHE reviewed 46 published full-text scientific publications for this guide. Every entry links directly to the source and shows who or what was studied, the dose, duration, design, and the result that matters for this page.
- Human intervention studies in women
- Broader human NMN intervention studies
- Systematic reviews and meta-analyses
- Human mechanistic and contextual research
- Female reproductive preclinical research
For readers who want to inspect the evidence
Showing all 46 publications.
Human Studies in Women 3 publications
A1-01
Yoshino et al., Science, 2021
- Population or model
- 25 postmenopausal women with overweight or obesity and prediabetes
- Design
- Randomized, double-blind, placebo-controlled trial
- Dose or intervention
- 250 mg/day
- Duration
- 10 weeks
Result relevant to this guide: Improved skeletal-muscle insulin sensitivity and insulin signaling and remodeling endpoints in this specific population.
Read full text
A2-02
Morita et al., Glycative Stress Research, 2022
- Population or model
- 17 postmenopausal women aged 50 to 80; 16 completed
- Design
- Single-arm, uncontrolled study
- Dose or intervention
- 300 mg/day after breakfast
- Duration
- 8 weeks
Result relevant to this guide: Reported selected biomarker and subjective skin, sleep, and fatigue signals; estradiol did not significantly change.
Read full text
A2-03
Fukumoto et al., Cosmetics, 2025
- Population or model
- 15 healthy Japanese women aged 40 to 50 with hair concerns
- Design
- Single-arm pre/post study
- Dose or intervention
- 500 mg/day
- Duration
- 12 weeks
Result relevant to this guide: Reported changes in selected hair measures and subjective hair quality and fatigue; preliminary because the study was small and uncontrolled.
Read full textBroader Human NMN Research 18 publications
B2-01
Irie et al., Endocrine Journal, 2020
- Population or model
- 10 healthy men
- Design
- Acute dose-escalation and pharmacokinetic safety study
- Dose or intervention
- Single 100, 250, or 500 mg dose
- Duration
- Hours
Result relevant to this guide: Found no major acute safety signal and characterized circulating metabolites after oral NMN.
Read full text
B1-02
Liao et al., Journal of the International Society of Sports Nutrition, 2021
- Population or model
- 48 amateur runners; female representation was small
- Design
- Randomized, double-blind, placebo-controlled trial with exercise training
- Dose or intervention
- 300, 600, or 1,200 mg/day
- Duration
- 6 weeks
Result relevant to this guide: Some ventilatory-threshold and submaximal performance measures favored medium or high doses; no universal peak-performance effect was established.
Read full text
B1-03
Okabe et al., Frontiers in Nutrition, 2022
- Population or model
- 30 healthy adults of both sexes
- Design
- Randomized, double-blind, placebo-controlled trial
- Dose or intervention
- 250 mg/day
- Duration
- 12 weeks
Result relevant to this guide: Increased whole-blood NAD+ with no major safety or laboratory concern; broad physiological benefit was not demonstrated.
Read full text
B1-04
Fukamizu et al., Scientific Reports, 2022
- Population or model
- 31 analyzed healthy adults of both sexes, aged 20 to 65
- Design
- Randomized, double-blind, placebo-controlled trial
- Dose or intervention
- 1,250 mg/day
- Duration
- 4 weeks
Result relevant to this guide: Reported no severe adverse events or clinically concerning safety trends over this short exposure.
Read full text
B1-05
Kim et al., Nutrients, 2022
- Population or model
- 108 older Japanese adults, men and women
- Design
- Randomized, double-blind, placebo-controlled morning/afternoon trial
- Dose or intervention
- 250 mg/day
- Duration
- 12 weeks
Result relevant to this guide: Reported selected lower-limb-function and drowsiness or timing signals; sleep, fatigue, and physical-function results were not uniformly positive.
Read full text
B1-06
Igarashi et al., npj Aging, 2022
- Population or model
- Healthy men aged 65 and older
- Design
- Randomized, double-blind, placebo-controlled trial
- Dose or intervention
- 250 mg/day
- Duration
- 12 weeks intended
Result relevant to this guide: Raised blood NAD-related metabolites and produced selected functional signals; an allocation error required a restricted later analysis.
Read full text
B1-07
Huang, Frontiers in Aging, 2022
- Population or model
- 66 healthy middle-aged or older adults; 62 completed
- Design
- Multicenter, randomized, double-blind, placebo-controlled trial
- Dose or intervention
- 300 mg/day
- Duration
- 60 days
Result relevant to this guide: Reported favorable NAD+/NADH and selected exploratory health outcomes.
Read full text
B1-08
Pencina et al., Journals of Gerontology Series A, 2023
- Population or model
- 32 adults aged 55 to 80 with overweight or obesity; 16 women and 16 men
- Design
- Double-blind, placebo-controlled, sex-stratified trial
- Dose or intervention
- 1,000 mg once or twice daily
- Duration
- 14 days
Result relevant to this guide: Clearly increased the circulating NMN and NAD metabolome; no significant sex difference in exposure was found in this small study.
Read full text
B1-09
Yi et al., GeroScience, 2023
- Population or model
- 80 healthy middle-aged adults with substantial female representation
- Design
- Randomized, multicenter, double-blind, placebo-controlled trial
- Dose or intervention
- 300, 600, or 900 mg/day
- Duration
- 60 days
Result relevant to this guide: Raised blood NAD at all doses and reported selected walking and quality-of-life differences; HOMA-IR did not significantly differ from placebo.
Read full text
B1-10
Katayoshi et al., 2023
- Population or model
- 36 healthy middle-aged adults of both sexes
- Design
- Randomized, double-blind, placebo-controlled trial
- Dose or intervention
- 250 mg/day
- Duration
- 12 weeks
Result relevant to this guide: Serum nicotinamide increased; no significant between-group arterial-stiffness effect was established.
Read full text
B1-11
Akasaka et al., Geriatrics & Gerontology International, 2023
- Population or model
- 14 older men with diabetes and impaired physical performance
- Design
- Placebo-controlled, double-blind trial
- Dose or intervention
- 250 mg/day
- Duration
- 24 weeks
Result relevant to this guide: Was tolerated but did not significantly improve grip strength, walking speed, or exploratory outcomes between groups.
Read full text
B2-12
Yamane et al., Clinical Nutrition ESPEN, 2023
- Population or model
- 11 healthy volunteers
- Design
- Single-arm study
- Dose or intervention
- 250 mg each morning
- Duration
- 12 weeks
Result relevant to this guide: Raised plasma NMN and NAD-related metabolites and reported a postprandial insulin signal with high person-to-person variability.
Read full text
B1-13
Pencina et al., physiologic study, 2024 publication record / full PMC
- Population or model
- 30 adults aged 45 and older with overweight or obesity
- Design
- Double-blind, randomized, placebo-controlled, sex-stratified trial
- Dose or intervention
- MIB-626, 1,000 mg twice daily
- Duration
- 28 days
Result relevant to this guide: Produced a large NAD metabolome rise and selected exploratory changes, but not significant improvement in measured fat depots or insulin sensitivity.
Read full text
B2-14
Qiu et al., Signal Transduction and Targeted Therapy, 2023
- Population or model
- Human hypertension comparison embedded in mouse and cell research
- Design
- Open randomized lifestyle comparison
- Dose or intervention
- 800 mg/day plus lifestyle modification
- Duration
- Short intervention; timing is reported inconsistently
Result relevant to this guide: Raised PBMC NAD+ and reported vascular signals in a very small human intervention; the reporting inconsistency affects interpretation.
Read full text
B2-15
Yamaguchi et al., Endocrine Journal, 2024
- Population or model
- Healthy Japanese men aged 40 to 60; 9 completed the active phase
- Design
- Single-center, single-arm, open-label study with placebo run-in
- Dose or intervention
- 250 mg/day before breakfast
- Duration
- 8 active-treatment weeks
Result relevant to this guide: Raised PBMC NAD+; sleep quality, glucose, insulin, and body composition did not significantly improve.
Read full text
B1-16
Morifuji et al., GeroScience, 2024
- Population or model
- 60 older adults
- Design
- Double-blind, randomized, placebo-controlled trial
- Dose or intervention
- 250 mg/day
- Duration
- 12 weeks
Result relevant to this guide: Raised blood NAD metabolites; the primary stepping-test endpoint was not significant, while selected walking and sleep measures were favorable.
Read full text
B1-17
Nakajima et al., Fundamental Toxicological Sciences, 2025
- Population or model
- 30 healthy men and women aged 20 to 64
- Design
- Randomized, double-blind, placebo-controlled trial
- Dose or intervention
- 750 or 1,500 mg/day
- Duration
- 4 weeks
Result relevant to this guide: Raised blood NAD with no clinically problematic short-term laboratory or adverse-event pattern and no meaningful telomere effect.
Read full text
B1-18
Yang et al., Journal of the International Society of Sports Nutrition, 2026
- Population or model
- 11 untrained young men
- Design
- Randomized, placebo-controlled, counterbalanced crossover trial
- Dose or intervention
- 1,200 mg/day
- Duration
- 7 days per condition
Result relevant to this guide: Altered exercise-related inflammatory and myogenic signals; this was a very small mechanistic study in young men.
Read full textSystematic Reviews and Syntheses 13 publications
C-01
Song et al., Advances in Nutrition, 2023
- Population or model
- Published human NMN clinical trials
- Design
- Narrative evidence synthesis
- Dose or intervention
- Varied across included studies
- Duration
- Varied across included studies
Result relevant to this guide: Mapped the early human trial landscape and separated published human outcomes from preclinical expectations.
Read full text
C-02
Chen et al., Current Diabetes Reports, 2024
- Population or model
- 8 randomized trials; 342 adults; about 49% female
- Design
- Systematic review and meta-analysis
- Dose or intervention
- 250 to 2,000 mg/day
- Duration
- 14 days to 12 weeks
Result relevant to this guide: Found no significant pooled benefit for fasting glucose, fasting insulin, HbA1c, HOMA-IR, or lipid profile.
Read full text
C-03
Sun et al., Nutrients, 2026
- Population or model
- 15 randomized adult NMN studies
- Design
- Systematic review and meta-analysis
- Dose or intervention
- 250 to 2,000 mg/day
- Duration
- 14 days to 24 weeks
Result relevant to this guide: Found studied-duration safety generally reassuring, without consistent broad benefit for weight or major metabolic outcomes.
Read full text
C-04
Prokopidis et al., Journal of Cachexia, Sarcopenia and Muscle, 2025
- Population or model
- Trials of NMN or nicotinamide riboside and muscle outcomes
- Design
- Systematic review and meta-analysis
- Dose or intervention
- Varied across included studies
- Duration
- Varied across included studies
Result relevant to this guide: Did not find significant pooled NMN improvement in muscle index, grip strength, gait speed, or chair-stand performance.
Read full text
C-05
Zhang et al., Nutrients, 2026
- Population or model
- 349 participants across 10 randomized trials and 11 intervention arms
- Design
- Systematic review and meta-analysis
- Dose or intervention
- Varied across included trials
- Duration
- Varied across included trials
Result relevant to this guide: Found no robust broad systolic-blood-pressure effect; modest diastolic signals and subgroups require caution.
Read full text
C-06
Freeberg et al., 2023
- Population or model
- Human studies of NAD+-boosting compounds
- Design
- Narrative review
- Dose or intervention
- Varied across included studies
- Duration
- Varied across included studies
Result relevant to this guide: Found NAD-related metabolites can be raised while physiological outcomes remain inconsistent across small, heterogeneous trials.
Read full text
C-07
Bhasin et al., Endocrine Reviews, 2023
- Population or model
- NAD biology, pharmacology, and human translation
- Design
- Authoritative scientific review
- Dose or intervention
- Not applicable
- Duration
- Not applicable
Result relevant to this guide: Explained the translational unknowns that prevent animal-model findings from establishing human anti-aging efficacy.
Read full text
C-08
Vinten et al., Nature Metabolism, 2025
- Population or model
- Human aging and NAD+ precursor evidence
- Design
- Scientific review
- Dose or intervention
- Varied across included studies
- Duration
- Varied across included studies
Result relevant to this guide: Found human age-related NAD decline is not uniform across tissues or populations and emphasized limited clinical outcome data.
Read full text
C-09
Peluso et al., Nutrients, 2022
- Population or model
- Human and translational evidence on age-related NAD+ patterns
- Design
- Critical scientific review
- Dose or intervention
- Not applicable
- Duration
- Not applicable
Result relevant to this guide: Found the human evidence for a universal predictable NAD+ decline sparse, tissue-specific, and often cross-sectional.
Read full text
C-10
EFSA NDA Panel, 2026
- Population or model
- Safety evidence for a specific beta-NMN novel-food ingredient and proposed use
- Design
- Regulatory scientific opinion
- Dose or intervention
- 300 mg/day use condition assessed
- Duration
- Not a consumer efficacy trial
Result relevant to this guide: Provides ingredient-specific regulatory safety context; it does not establish an optimal NMN dose or U.S. regulatory status.
Read full text
C-11
Noh et al., Journal of Assisted Reproduction and Genetics, 2026
- Population or model
- Preclinical oocyte interventions plus human transcriptomic context
- Design
- Systematic review and transcriptomic analysis
- Dose or intervention
- Varied across preclinical studies
- Duration
- Varied across preclinical studies
Result relevant to this guide: Found the supplementation interventions were preclinical; human transcriptomics were not a human supplementation efficacy trial.
Read full text
C-12
Cordone et al., Biology of Reproduction, 2026
- Population or model
- Ovarian NAD biology, aging, PCOS, and ovarian insufficiency evidence
- Design
- Scientific review
- Dose or intervention
- Not applicable
- Duration
- Not applicable
Result relevant to this guide: Concluded that well-designed human studies directly evaluating fertility effects remain lacking.
Read full text
C-13
Liang et al., 2023
- Population or model
- Ovarian aging and NAD+ metabolism research
- Design
- Scientific review
- Dose or intervention
- Not applicable
- Duration
- Not applicable
Result relevant to this guide: Mapped ovarian NAD biology and found translational human supplementation evidence remains limited.
Read full textHuman Context and Mechanism 4 publications
D-01
Clement et al., 2019
- Population or model
- Healthy humans from young to older adulthood
- Design
- Cross-sectional metabolomics study
- Dose or intervention
- No supplementation intervention
- Duration
- Cross-sectional sampling
Result relevant to this guide: Found age associations in plasma NAD-related metabolites, while plasma NMN did not show a simple universal age decline.
Read full text
D-02
Massudi et al., PLOS One, 2012
- Population or model
- Human skin tissue from newborn to older ages
- Design
- Cross-sectional tissue study
- Dose or intervention
- No supplementation intervention
- Duration
- Cross-sectional sampling
Result relevant to this guide: Found age-related associations in skin NAD biology and oxidative-stress markers; this was one tissue, not a whole-body decline curve.
Read full text
D-03
Smits et al., Human Reproduction, 2023
- Population or model
- Human ovarian tissue biopsies and oocytes
- Design
- Human tissue and mechanistic study
- Dose or intervention
- No NMN supplementation intervention
- Duration
- Cross-sectional tissue analysis
Result relevant to this guide: Associated advanced maternal age with oxidative damage and mitochondrial dysfunction; it did not test NMN efficacy.
Read full text
D-04
Endocrine Society Scientific Statement, 2023
- Population or model
- Endocrine aging, menopause, ovarian senescence, and hormone therapy evidence
- Design
- Authoritative scientific statement
- Dose or intervention
- Not applicable
- Duration
- Not applicable
Result relevant to this guide: Provides clinical context that keeps menopause biology and hormone therapy distinct from NMN supplementation.
Read full textFemale Reproductive Preclinical Research 8 publications
E-01
Bertoldo et al., Cell Reports, 2020
- Population or model
- Aged female mice
- Design
- Preclinical animal study
- Dose or intervention
- NMN in chronic drinking-water and acute experiments
- Duration
- Acute and chronic protocols
Result relevant to this guide: Improved selected oocyte, embryo-development, and fertility outcomes in aged mice; this does not establish human fertility benefit.
Read full text
E-02
Uddin et al., Scientific Reports, 2017
- Population or model
- Female mouse offspring in a maternal-obesity model
- Design
- Preclinical animal study
- Dose or intervention
- High-dose injected NMN
- Duration
- Protocol-specific
Result relevant to this guide: Changed selected metabolic, liver, and adiposity outcomes in mice; direct relevance to women taking oral NMN is low.
Read full text
E-03
Wang et al., Cell Proliferation, 2022
- Population or model
- Female mice with high-fat-diet obesity
- Design
- Preclinical animal study
- Dose or intervention
- NMN; protocol-specific dose
- Duration
- Protocol-specific
Result relevant to this guide: Improved selected oocyte mitochondrial, oxidative, spindle, DNA-damage, and ovarian-inflammatory outcomes in mice.
Read full text
E-04
Jiang et al., Cell Proliferation, 2023
- Population or model
- Mouse reproductive model exposed to benzyl butyl phthalate
- Design
- Preclinical animal study
- Dose or intervention
- NMN; protocol-specific dose
- Duration
- Protocol-specific
Result relevant to this guide: Mitigated selected mitochondrial, oxidative, DNA-damage, apoptosis, and oocyte outcomes in the mouse model.
Read full text
E-05
Guo et al., Nutrition & Diabetes, 2024
- Population or model
- Female mice with type 1 diabetes
- Design
- Preclinical animal study
- Dose or intervention
- NMN; protocol-specific dose
- Duration
- Protocol-specific
Result relevant to this guide: Improved selected oocyte maturation and quality-related outcomes in mice.
Read full text
E-06
Li et al., PLOS One, 2023
- Population or model
- Porcine oocytes
- Design
- Preclinical non-human oocyte study
- Dose or intervention
- Beta-NMN; protocol-specific dose
- Duration
- Protocol-specific
Result relevant to this guide: Improved selected oxidative, mitochondrial, apoptosis, and embryo-development outcomes in an aged porcine-oocyte model.
Read full text
E-07
Xu et al., Antioxidants, 2023
- Population or model
- Vitrified bovine oocytes in vitro
- Design
- Preclinical in-vitro study
- Dose or intervention
- Beta-NMN; protocol-specific dose
- Duration
- Protocol-specific
Result relevant to this guide: Improved selected survival, development, and oxidative-stress outcomes after vitrification; direct consumer relevance is very low.
Read full text
E-08
Shen et al., Journal of Ovarian Research, 2025
- Population or model
- Female mice exposed to cyclophosphamide
- Design
- Preclinical animal study
- Dose or intervention
- NMN; protocol-specific dose
- Duration
- Protocol-specific
Result relevant to this guide: Improved selected ovarian and embryo-development outcomes in mice; it does not establish fertility preservation in women receiving chemotherapy.
Read full textHow to read this library: Human interventions, evidence syntheses, human context, and preclinical findings answer different questions. Animal and oocyte findings explain scientific interest, but they are not evidence that NMN improves fertility or ovarian outcomes in women.
A living evidence review
How We Built This Guide
This page starts with human evidence.
Women-specific human trials receive priority when answering a question specifically about women.
Broader human research is used to understand NAD+ response, dosing, safety, and outcomes that have not yet been studied adequately in women-only trials.
Animal and laboratory research is kept separate from human evidence.
Conference abstracts, unpublished trials, registry-only studies, and thin evidence are excluded from the public 46-publication corpus.
We also record study design, population, dose, duration, important endpoints, and relevant commercial relationships.
The goal is simple: make the evidence easy to understand first, and easy to audit second.
Review change log
September 2026- Initial 46-publication review published.
- Women-specific evidence, dosage, menopause, safety, and product decision guidance established.
- Editorial presentation rebuilt to prioritize reader comprehension and decision utility.
Written by
CELLSHE Editorial Team
Author
CELLSHE creates evidence-led healthy-aging resources for women and maintains the scientific review system behind this guide.
Editorially reviewed by
CELLSHE Editorial Team
Editorial review
Editorially reviewed for evidence quality, scientific interpretation, source accuracy, and clear separation between human and preclinical findings.
Review scope: The editorial review checks source quality, study interpretation, and whether the page reflects the evidence reviewed. This guide is educational and does not replace individual medical care.
Page review date: September 3, 2026. The literature search date remains September 3, 2026 until the scientific corpus is formally updated.
Direct answers
Frequently Asked Questions About NMN for Women
Is NMN good for women over 40?
NMN can be a reasonable healthy-aging supplement for women over 40 who want to support NAD+ biosynthesis. Women in their 40s and 50s have been studied directly, and 500 mg/day has been used in a women-only study.
Is NMN good for women over 50?
Women over 50 are represented in published NMN research, including postmenopausal women. The strongest women-specific controlled trial studied postmenopausal women and found improved skeletal-muscle insulin sensitivity after 10 weeks.
Does NMN raise NAD+?
Yes. This is the most consistent finding across human NMN trials. Multiple controlled studies have found higher blood NAD+ or related metabolites after oral NMN.
What is beta-NMN?
Beta-NMN, or β-NMN, is the beta form of nicotinamide mononucleotide used in many human NMN studies. “Beta” describes the molecule's configuration. It does not mean a stronger or higher-dose version of NMN.
Will I feel NMN working?
Possibly, but NMN should not be expected to feel like caffeine.
Its strongest human evidence involves measured biological changes rather than an immediate stimulant effect.
Some smaller studies have reported changes in sleep or fatigue, so individual experience can differ.
How long does NMN take to work?
Blood NAD-related measures have changed within weeks in human studies.
That does not mean every person will notice a subjective change on the same timeline.
Think of NMN as a consistent daily routine rather than a same-day supplement.
Is 500 mg of NMN a lot?
500 mg sits within the range studied in humans.
It has also been used directly in a women-only study.
That makes it a research-grounded daily amount, not an arbitrary front-label number.
Does NMN increase estrogen?
A small study in postmenopausal women measured estradiol directly and did not find a significant increase.
NMN is used as an NAD+ precursor, not as an estrogen supplement.
Can NMN help with menopause?
NMN has been studied in postmenopausal women, including in a randomized metabolic trial.
Its role is better understood as cellular and healthy-aging support than as a treatment for menopause symptoms.
Can I take NMN with HRT?
Human research has not established a special combination benefit from NMN plus hormone therapy.
If you use prescription HRT, review the complete supplement label with the clinician managing your treatment.
Does NMN help with weight loss?
Weight loss is not an established NMN effect in human trials.
If weight loss is your main goal, choose an approach designed for that goal.
Does NMN improve fertility?
Most intervention research involving NMN and ovarian aging is still preclinical.
NMN is not an established fertility treatment.
Is NMN safe?
Short-term human evidence is generally reassuring.
A 2026 pooled analysis of randomized trials found no significant increase in overall or serious adverse events compared with control.
Longer-term human data are still accumulating.
The practical conclusion
The Bottom Line on NMN for Women
NMN becomes much easier to understand once you separate the core evidence from the longevity noise.
Your body uses NMN to make NAD+.
Taking NMN raises NAD+ or related metabolites in human studies.
Women have been studied directly.
The strongest women-specific trial found improved skeletal-muscle insulin sensitivity in postmenopausal women with prediabetes.
Women-specific studies have used 250 mg, 300 mg, and 500 mg per day.
If you want a straightforward NMN product, 500 mg of beta-NMN in one transparent, independently tested capsule is a strong research-grounded option.
CELLSHE NMN 500 was built around exactly that idea.
- 500 mg beta-NMN
- One capsule
- Third-party tested
- COA available
- 60-Day Guarantee
30 capsules. No recurring delivery.
Monthly delivery through the intended Appstle plan.
Core sources
References
These 20 core sources support the page’s main claims and evidence boundaries. See the complete 46-publication evidence library for every included full-text publication.
- Yoshino J, et al. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science.
- Morita N, et al. (2022). Clinical evaluation of changes in biomarkers by oral intake of NMN. Glycative Stress Research.
- Fukumoto S, et al. (2025). Oral Supplementation of Nicotinamide Mononucleotide (NMN) Improves Hair Quality and Subjective Perception of Hair Appearance in Middle-Aged Women. Cosmetics.
- Okabe K, et al. (2022). Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects. Frontiers in Nutrition.
- Yi L, et al. (2023). The efficacy and safety of beta-nicotinamide mononucleotide supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience.
- Kim M, et al. (2022). Effect of 12-Week Intake of Nicotinamide Mononucleotide on Sleep Quality, Fatigue, and Physical Performance in Older Japanese Adults: A Randomized, Double-Blind Placebo-Controlled Study. Nutrients.
- Morifuji M, et al. (2024). Ingestion of beta-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults in a double-blind randomized, placebo-controlled study. GeroScience.
- Chen X, et al. (2024). Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials. Current Diabetes Reports.
- Sun P, et al. (2026). Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis. Nutrients.
- Pencina KM, et al. (2023). MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of beta-Nicotinamide Mononucleotide, Increases Circulating Nicotinamide Adenine Dinucleotide and its Metabolome in Middle-Aged and Older Adults. The Journals of Gerontology: Series A.
- Fukamizu Y, et al. (2022). Safety evaluation of beta-nicotinamide mononucleotide oral administration in healthy adult men and women. Scientific Reports.
- Katayoshi T, et al. (2023). Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial. Scientific Reports.
- Akasaka H, et al. (2023). Effects of nicotinamide mononucleotide on older patients with diabetes and impaired physical performance: A prospective, placebo-controlled, double-blind study. Geriatrics & Gerontology International.
- Prokopidis K, et al. (2025). The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis. Journal of Cachexia, Sarcopenia and Muscle.
- Bhasin S, et al. (2023). Nicotinamide Adenine Dinucleotide in Aging Biology: Potential Applications and Many Unknowns. Endocrine Reviews.
- Vinten APB, et al. (2025). NAD+ precursor supplementation in human ageing. Nature Metabolism.
- Peluso A, et al. (2022). Age-Dependent Decline of NAD+: Universal Truth or Confounded Consensus? Nutrients.
- Endocrine Society (2023). Hormones and Aging: An Endocrine Society Scientific Statement. The Journal of Clinical Endocrinology & Metabolism.
- Noh S, et al. (2026). NMN supplementation as a strategy to improve oocyte quality: systematic review and transcriptomic analysis. Journal of Assisted Reproduction and Genetics.
- Bertoldo MJ, et al. (2020). NAD+ Repletion Rescues Female Fertility during Reproductive Aging. Cell Reports.